Boston Life Sciences, Inc. To Present At Friedland Investment Events East Coast Biotech, Medical And Healthcare Luncheons

Boston Life
Sciences, Inc. (Nasdaq: BLSI), a biotechnology company focused on
diagnostic and therapeutic products for diseases of the Central Nervous
System (CNS), today announced that it will be presenting at Friedland
Investment Events East Coast Biotech, Medical and Healthcare Luncheons on
July 18th, 19th and 20th in Philadelphia, New York and Boston. Dr. Mark
Pykett, President & Chief Operating Officer, or Mr. Ken Rice, Executive
Vice President and Chief Financial Officer, will be presenting a Company
update which will include a review of the company's products, management
and recent company developments.


Registration is required to attend these luncheons. Complimentary
tickets are available to members of the financial community and select
investors by applying online at friedlandworldwide.


About Friedland Investment Events


Friedland Investment Events LLC is the world's largest sponsor of
financial and investment events, sponsoring hundreds of events annually, in
18 US cities and 3 European cities. These events include all-day
conferences, breakfasts, luncheons and cocktail receptions. Friedland
Investment Events LLC is an affiliate of Friedland Capital Inc. and
Friedland Corporate Investor Services LLC
(friedlandworldwide).


About Friedland Capital


Friedland Capital Inc. is a U.S.-based merchant bank and advisory firm
with offices or affiliates in New York, Dallas, Denver, Los Angeles,
Beijing and Guangzhou. Among its activities, Friedland Capital provides
corporate finance advisory services to enable publicly-traded and
privately-held emerging growth companies, as well as sponsors of investment
programs worldwide to achieve their short-term capital goals, and to
realize their long-term business objectives.


About Boston Life Sciences, Inc.


Boston Life Sciences, Inc. (BLSI) is engaged in the research and
clinical development of diagnostic and therapeutic products for central
nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in
Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS)
and a Phase II clinical trial for the diagnosis of Attention Deficit
Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS
programs include Inosine for the treatment of stroke, a DAT blocker for the
treatment of Parkinson's disease and a second generation technetium-based
molecular imaging agent for PS and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's Hospital of
Boston.


ALTROPANE is a registered trademark of Boston Life Sciences, Inc.
The foregoing release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements regarding Boston Life
Sciences' expectations, beliefs, intentions or strategies regarding the
future, including the Company's development efforts regarding the Company's
ALTROPANE program and the Company's pre-clinical candidates.
Forward-looking statements can be identified by terminology such as
"anticipate," "believe," "could," "could increase the likelihood,"
"estimate," "expect," "intend," "is planned," "may," "should," "will,"
"will enable," "would be expected," "look forward," "may provide," "would"
or similar terms, variations of such terms or the negative of those terms.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors including those risks, uncertainties and
factors referred to in the Company's Quarterly Report on form 10-Q for the
quarter ended September 30, 2005, filed with the Securities and Exchange
Commission under the section "Risk Factors," as well as other documents
that may be filed by Boston Life Sciences from time to time with the
Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements discussed
in or implied by the forward-looking statements contained herein. Boston
Life Sciences, Inc. is providing the information in this press release as
of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of
new information, future events or otherwise.


Boston Life Sciences, Inc.

bostonlifesciences/